Advertisement

Search Results

Advertisement



Your search for The A matches 22955 pages

Showing 1 - 50


ASCO Statement on 2021 Annual Meeting

ASCO has announced that the 2021 ASCO Annual Meeting will be an online-only experience, taking place from June 4 to 8, 2021. The Society issued the following statement on the Meeting: We had hoped for a return to an in-person meeting, as we all miss the opportunity to see and engage with our...

skin cancer

Small Study Finds Personalized Neoantigen Vaccines May Result in Durable Immune Response for Patients With Melanoma

Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response caused by the vaccine remained robust and effective in keeping cancer cells under control, according to a new study published by Hu et al in Nature Medicine. The findings demonstrate the...

covid-19

Patients in Cancer Remission Also at Higher Risk for Severe COVID-19 Illness

Patients with inactive cancer who are not currently undergoing treatment also face a significantly higher risk of severe illness from COVID-19, according to a new study published by Sun et al in JNCI Cancer Spectrum. The findings underscore the importance of COVID-19 mitigation, like social...

lung cancer

Study Identifies Four Unique Subtypes of Small Cell Lung Cancer

Researchers have developed the first comprehensive framework to classify small cell lung cancer (SCLC) into four unique subtypes based on gene expression and have identified potential therapeutic targets for each type. These findings were published by Gay et al in Cancer Cell. SCLC is known for...

head and neck cancer

Emergency Department Use and Unplanned Hospitalization Among Patients With Head and Neck Cancer: Association With Reported Symptom Burden

In a Canadian population-based study reported in the Journal of Clinical Oncology, Noel et al found that patient-reported symptom burden was significantly associated with the likelihood of emergency department use and unplanned hospitalization among patients with head and neck cancer. Study ...

breast cancer
genomics/genetics

Prevalence of and Risk Associated With Breast Cancer Predisposition Genes: U.S. Population-Based Study

In a U.S. population-based, case-control study reported in The New England Journal of Medicine, Hu et al identified the prevalence of and risk associated with germline pathogenic variants in established and candidate breast cancer predisposition genes. Study Details The study involved 32,247 women...

leukemia
immunotherapy
symptom management

Preemptive Tocilizumab for Cytokine-Release Syndrome in Pediatric Patients With B-Cell ALL Receiving CAR T-Cell Therapy

In a single-institution study reported in the Journal of Clinical Oncology, Kadauke et al found that risk-adapted tocilizumab reduced the expected incidence of grade 4 cytokine-release syndrome in pediatric patients receiving CD19-directed chimeric antigen receptor (CAR) T-cell...

It All Began With a Lump in the Throat

BOOKMARK Title: Milkshakes and Morphine: A Memoir of Love and LifeAuthor: Genevieve FoxPublisher: VintagePublication date: January 2019Price: $15.95, paperback, 384 pages “It doesn’t hurt, but I know it is there and I know it shouldn’t be. Interloper. I have touched it a couple of times already,...

survivorship

New NCCN Resource Offers Practical Suggestions for Cancer Survivors

The National Comprehensive Cancer Network (NCCN) has announced the publication of new, free informational resources on health and wellness for cancer survivors. These two new NCCN Guidelines for Patients® are focused on healthy living and managing late and long-term side effects, and they include...

breast cancer

Finding Hope With Cancer

Sometimes there just is no escaping cancer. I thought I had done everything right. I was diligent about adhering to my annual physical exams, including mammograms, and routinely performed breast self-exams to spot any early changes in my breasts. Still, in the summer of 2015, I was diagnosed with...

Sarah Cannon Names Melissa Johnson, MD, Program Director of Lung Cancer Research

Sarah Cannon recently announced that Melissa ­Johnson, MD, has been named Program Director of Lung Cancer Research. In her new role, Dr. Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network. Dr. Johnson has served as Associate Director of Lung Cancer Research...

Mayo Clinic Care Network Expands to Include Minnesota Oncology

The first independent, community oncology practice recently joined the Mayo Clinic Care Network. Minnesota Oncology comprises a group of carefully vetted, independent health-care providers with special access to the Mayo Clinic’s knowledge and expertise, including its research, diagnostic, and...

Kenneth H. Kim, MD, to Lead Cedars-Sinai Women’s Cancer Program

Cedars-Sinai Cancer Center has announced that Kenneth H. Kim, MD, will direct its Division of Gynecologic Oncology. Dr. Kim also serves as Chair of the institution’s Committee for Oversight of Training and Education. The appointment reflects Dr. Kim’s breadth of experience, which involves novel...

CDC Awards Huntsman Cancer Institute $3 Million to Improve Colorectal Cancer Screening

Huntsman Cancer Institute (HCI) at the University of Utah has been awarded a 5-year, $3 million grant from the Centers for Disease Control and Prevention (CDC) to improve Utah’s colorectal cancer screening rates. The program will build on an ongoing partnership between HCI’s Center for Health...

Huntsman Cancer Institute Appoints Cancer Center Research Program Leaders

Huntsman Cancer Institute (HCI) at the University of Utah recently announced that Jay Gertz, PhD, and Trudy G. Oliver, PhD, have accepted invitations to serve as co-leaders of HCI Comprehensive Cancer Center research programs. Dr. Gertz will serve alongside Jared Rutter, PhD, as co-leader of the...

Expect Questions About Adjuvant Chemotherapy for Older Women

Two recent studies found significant survival benefits for patients older than 70 years with surgically treated nonmetastatic triple-negative breast cancer who also received chemotherapy.1,2 The authors of both studies concluded that the findings support the consideration of chemotherapy for older...

breast cancer

Significant Survival Benefit From Chemotherapy for Older Women With Triple-Negative Breast Cancer

Women older than age 70 diagnosed with triple-negative breast cancer had significantly improved overall survival if they received adjuvant and/or neoadjuvant chemotherapy, according to an analysis of data from more than 16,000 women enrolled in the National Cancer Database. The estimated 5-year...

AAAS Announces Leading Scientists Elected as 2020 Fellows

Nearly 500 members of the American Association for the Advancement of Science (AAAS) have earned the lifetime distinction of AAAS Fellow. The Fellows are elected each year by their peers serving on the Council of AAAS, the organization’s member-run governing body. The title recognizes important...

Julie Gralow, MD, on Goals as ASCO CMO

Julie Gralow, MD, of the University of Washington, discusses her goals as ASCO’s newly appointed Chief Medical Officer and delivers a personal message to the Society’s members.

breast cancer

Chemotherapy Added to Local Therapy Improves Overall Survival in Older Women With Triple-Negative Breast Cancer

In a National Cancer Database analysis reported in The Lancet Oncology, Jennifer A. Crozier, MD, of the Division of Cancer Medicine, Baptist MD Anderson Cancer Center, Jacksonville, and colleagues found that receipt of neoadjuvant or adjuvant chemotherapy was associated with improved overall...

colorectal cancer

Duration of Adjuvant Chemotherapy Assessed in Stage III Colon Cancer

As reported in The Lancet Oncology by Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues, the prospective pooled analysis of six phase III trials in the IDEA collaboration has shown that noninferiority in overall survival for 3 vs 6 months of adjuvant...

colorectal cancer

High Recurrence-Free Survival Rates in Rectal Cancer After Clinical Complete Response to Neoadjuvant Chemoradiotherapy

In a study reported in The Lancet Oncology, Laura M. Fernandez, MD, of Champalimaud Foundation, Lisbon, and colleagues found high rates of conditional recurrence-free survival during watch-and-wait surveillance among patients with rectal cancer who maintained a clinical complete response to...

Winners of 40 Under 40 in Cancer Awards Announced

40 Under 40 in cancer is an awards initiative to identify and recognize contributions from across the field of oncology by approximately rising stars and emerging leaders younger than 40. Awardees were nominated by colleagues and selected by a panel of reviewers from a range of areas in oncology....

breast cancer

Expert Point of View: C. Kent Osborne, MD, and Ruth M. O’Regan, MD

Commentary for monarchE and PENELOPE-B was provided by C. Kent Osborne, MD, and Ruth M. O’Regan, MD, respectively. Dr. Osborne is Professor of Medicine, Hematology, and Oncology and the Dudley and Tina Sharp Chair for Cancer Research at Baylor College of Medicine, as well as Founding Director of...

breast cancer

A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer

The primary outcome analysis of the phase III monarchE trial, an update of previous data, continued to show significant benefit for abemaciclib in the adjuvant setting, reducing the risk for invasive disease recurrence by 28.7%. Meanwhile, the first results of the phase III PENELOPE-B trial of...

Erratum

In the December 10, 2020, issue of The ASCO Post, an article about Shilpi Gupta, MD, joining Atlantic Health System Cancer Care’s comprehensive breast health program included a photo of Shilpa Gupta, MD, an oncologist at Cleveland Clinic. The correct photo appears here. We apologize to both...

Research Leader Named to Rutgers Cancer Institute to Build ‘World-Class’ Cancer Immunology and Immunotherapy Programs

Rutgers Cancer Institute of New Jersey has named Christian Hinrichs, MD, as Chief of the Section of Cancer Immunotherapy and Co-Director of the Cancer Immunology and Metabolism Center of Excellence, along with Eileen White, PhD, Deputy Director and Chief Scientific Officer at Rutgers Cancer...

global cancer care

Indian Surgical Oncologist Offers Insights Into Delivering Equitable Cancer Care in a Resource-Challenged Country

The ASCO Post is pleased to introduce this department on Global Health-Care Equity. On an occasional basis, we will publish interviews between Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, and another oncologist or cancer care specialist spanning regions around the world. Our goal is to...

lung cancer

Osimertinib in Adjuvant Therapy for NSCLC With EGFR Mutations

On December 18, 2020, osimertinib was approved for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) with tumors with EGFR exon 19 deletions or exon 21 L858R mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 Supporting...

Association of Community Cancer Centers Announces New Senior Director

The Association of Community Cancer Centers (ACCC) recently appointed Kristin Ferguson, DNP, RN, OCN, as Senior Director, Cancer Care Delivery and Health Policy. Dr. Ferguson will lead the organization’s initiatives to improve cancer care delivery across rural, urban, and underresourced settings,...

multiple myeloma
immunotherapy

Expert Point of View: Sagar Lonial, MD, and Adam D. Cohen, MD

The studies of ALLO-715 “off-the-shelf” CAR T-cell therapy and bb21217 impressed two experts in the field. Sagar Lonial, MD, the Anne and Bernard Gray Family Chair in Cancer, Chair and Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, and Adam D. Cohen, MD, ...

Researchers Use Artificial Intelligence in Oral Cancers With $3.3 Million NIH Grant

Researchers at Case Western Reserve University and partners in the United States and India are applying the investigative and predictive capabilities of artificial intelligence (AI) to help physicians customize treatments for patients with oral squamous cell carcinomas. Research shows that oral...

multiple myeloma
immunotherapy

Novel Anti-BCMA CAR T-Cell Therapies Show Activity in Myeloma

In the treatment of relapsed or refractory multiple myeloma, chimeric antigen receptor (CAR) T-cell therapies with unique characteristics, still targeting B-cell maturation antigen (BCMA), are looking promising. At the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition,...

Innovation Discovery Grants Awarded to Mass General Brigham for Scientific Advancements in 2020

Five Innovation Discovery Grants (IDG) have been awarded to faculty from Mass General Brigham for scientific advancements, as the highly competitive IDG program exceeds $3.5 million in grants since inception. Each of the five potential patient health and health-care delivery breakthroughs for 2020...

AMA Statement on the Nominations of Xavier Becerra, JD, as HHS Secretary and Vivek Murthy, MD, as U.S. Surgeon General

Russ Kridel, MD, Chair of the American Medical Association (AMA) Board of Trustees, recently released the following statement on December 17, 2020: The American Medical Association strongly supports the nominations of Xavier Becerra, JD, to be the next Secretary of Health and Human Services (HHS)...

leukemia

Expert Point of View: Marlise Luskin, MD

Commenting on this trial, Marlise Luskin, MD, of Dana-Farber Cancer Institute, Boston, explained that the treatment of AML in older adults remains a particular challenge for leukemia clinicians. “Although many older patients eligible for intensive induction chemotherapy achieve complete remission,...

multiple myeloma

Venetoclax Added to Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

As reported in The Lancet Oncology by Shaji K. Kumar, MD, of the Division of Hematology, Mayo Clinic, Rochester, and colleagues, the phase III BELLINI trial has shown that the addition of venetoclax to bortezomib/dexamethasone significantly prolonged progression-free survival in patients with...

leukemia

Oral Azacitidine Is Noninferior to Placebo for Health-Related Quality of Life in AML

Health-related quality of life was sustained in patients taking oral azacitidine (also known as CC-486) compared with placebo in patients with acute myeloid leukemia (AML), according to results of the phase III QUAZAR AML-001 trial reported at the 2020 American Society of Hematology (ASH) Annual...

AMA Underscores Need for Coordinated, Comprehensive Pandemic Response

In a national address delivered on January 12, 2021, American Medical Association (AMA) President Susan R. Bailey, MD, outlined immediate action necessary for a coordinated, comprehensive federal response to the COVID-19 pandemic. The address, titled “COVID-19: The Long Road to Recovery,” focused...

multiple myeloma

Expert Point of View: Suzanne Lentzsch, MD, PhD

IFM 2009 showed that autologous stem cell transplant (ASCT) combined with lenalidomide, bortezomib, and dexamethasone (RVd) results in a significantly better progression-free survival than RVd alone in newly diagnosed patients with myeloma.1 “The data favor immediate ASCT, as transplant resulted in ...

City of Hope Announces Its First Chief Diversity, Equity, and Inclusion Officer

City of Hope, an independent cancer and diabetes research and treatment center, has welcomed Angela L. Talton, MBA, to its executive leadership team as Senior Vice President and Chief Diversity, Equity, and Inclusion Officer. Ms. Talton will provide leadership for City of Hope’s efforts to build a...

multiple myeloma

Long-Term Follow-up of IFM 2009 Confirms Benefit of Front-Line Transplant in Myeloma

The benefit of autologous transplantation in newly diagnosed multiple myeloma has been confirmed by follow-up of the IFM 2009 trial, reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition by Aurore Perrot, MD, PhD, Assistant Professor of Hematology at the Cancer...

Expert Point of View: Yuan Yuan, MD, PhD

Yuan Yuan, MD, PhD, a medical oncologist at City of Hope, Duarte, California, commented on the IPATunity130 trial. “Targeting the PIK3CA/AKT/mTOR cancer driver pathway is the holy grail for breast cancer in general. About 30% to 40% of breast cancers carry an alteration. Activation of this pathway ...

breast cancer

Ipatasertib Plus Paclitaxel Falters in Advanced Triple-Negative Breast Cancer Phase III Trial

The combination of ipatasertib plus paclitaxel failed to improve progression-free survival in PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer, according to results from cohort A of the phase III IPATunity130 trial, presented at the 2020 San...

breast cancer

Expert Point of View: Yuan Yuan, MD, PhD

Yuan Yuan, MD, PhD, a medical oncologist at City of Hope, Duarte, California, said that this was yet another failed phase III trial following promising phase II data. “Entinostat was granted Fast Track designation by the U.S. Food and Drug Administration several years back based on preclinical and...

breast cancer

Adding Entinostat to Exemestane Fails to Overcome Aromatase Inhibitor Resistance in Advanced Breast Cancer

The histone deacetylase inhibitor (HDAC) entinostat, added to exemestane, failed to overcome endocrine therapy resistance in advanced breast cancer, according to the E2112 phase III trial conducted by the ECOG-ACRIN Cancer Research Group. Results showed that overall survival was not improved by the ...

Expert Point of View: Yuan Yuan, MD, PhD, and Elizabeth Mittendorf, MD, PhD

Yuan Yuan, MD, PhD, a medical oncologist at City of Hope, Duarte, California, weighed in on the KEYNOTE-355 findings. “The study presented by Dr. Rugo on KEYNOTE-355 reconfirms the utility of adding immune checkpoint inhibitorsto chemotherapy as front-line treatment for metastatic triple-negative...

breast cancer

Expert Point of View: Hatem Soliman, MD

“The updated long-term follow-up from IBIS II showed that tamoxifen and anastrozole have similar efficacy in preventing breast cancer recurrences in patients diagnosed with ductal carcinoma in situ. However, there were differences in side effects consistent with the known safety profiles of these...

breast cancer

KEYNOTE-355: Pembrolizumab Plus Chemotherapy Improves Progression-Free Survival in PD-L1–Enriched Advanced Triple-Negative Breast Cancer

Pembrolizumab plus chemotherapy improved progression-free survival vs chemotherapy alone as first-line treatment of advanced or metastatic triple-negative breast cancer, according to the results of KEYNOTE-355.1 Progression-free survival was significantly improved with pembrolizumab plus...

breast cancer

Anastrozole vs Tamoxifen to Prevent DCIS Recurrence: Key Difference May Be Side-Effect Profile

If your patient were an older woman opting for hormonal therapy after surgically excised ductal carcinoma in situ (DCIS), which hormonal agent would you recommend for the prevention of disease recurrence: tamoxifen or anastrozole? According to long-term follow-up of the large, randomized IBIS...

Advertisement

Advertisement



Advertisement